tradingkey.logo
搜尋

Bluejay Diagnostics Inc

BJDX
添加自選
1.140USD
-0.060-5.00%
收盤 07/02, 13:00美東報價延遲15分鐘
172.29K總市值
虧損本益比TTM

Bluejay Diagnostics Inc

1.140
-0.060-5.00%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-5.00%

5天

-61.09%

1月

-74.72%

6月

-56.46%

今年開始到現在

-57.28%

1年

-30.06%

關鍵數據
1.180今開
1.210最高
321.90K成交量
虧損本益比TTM
--本益比動
--股利TTM
212.99%換手率
1.200昨收
1.030最低
268.00K成交額
虧損本益比靜
0.03市淨率
0.00%股息率 TTM
-126.94%ROA
16.68052週最高
0.59量比
-34.16M淨利潤
151.13K總股本
-49.4930每股盈餘TTM
0.81Beta
-171.56%ROE
1.62352週最低
15.00%振幅
19.64%毛利率
172.29K總市值
-11.86回報/風險
6.52%風險率

TradingKey Bluejay Diagnostics Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Bluejay Diagnostics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名250/387位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Bluejay Diagnostics Inc評分

相關信息

行業排名
250 / 387
全市場排名
537 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Bluejay Diagnostics Inc亮點

亮點風險
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
估值合理
公司最新PE估值-0.02,處於3年歷史合理位
機構加倉
最新機構持股42.23K股,環比增加23.42%

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間

Bluejay Diagnostics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Bluejay Diagnostics Inc簡介

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
公司代碼BJDX
公司Bluejay Diagnostics Inc
CEODey (Neil)
網址https://bluejaydx.com/

常見問題

Bluejay Diagnostics Inc(BJDX)的當前股價是多少?

Bluejay Diagnostics Inc(BJDX)的當前股價是 1.14。

Bluejay Diagnostics Inc 的股票代碼是什麼?

Bluejay Diagnostics Inc的股票代碼是BJDX。

Bluejay Diagnostics Inc股票的52週最高點是多少?

Bluejay Diagnostics Inc股票的52週最高點是16.68。

Bluejay Diagnostics Inc股票的52週最低點是多少?

Bluejay Diagnostics Inc股票的52週最低點是1.62。

Bluejay Diagnostics Inc的市值是多少?

Bluejay Diagnostics Inc的市值是1.18M。

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是多少

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是-61.01。